Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis

详细信息    查看全文

• 作者：Malliga R. IyerResat Cinar ; Alexis Katz ; Michael Gao ; Katalin Erdelyi ; Tony Jourdan ; Nathan J. Coffey ; Pal Pacher ; George Kunos
• 刊名：Journal of Medicinal Chemistry
• 出版年：2017
• 出版时间：February 9, 2017
• 年：2017
• 卷：60
• 期：3
• 页码：1126-1141
• 全文大小：860K
• ISSN：1520-4804

文摘

We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB<sub>1sub>R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB<sub>1sub> receptor (CB<sub>1sub>R) binding assays and iNOS activity assays. The novel compounds, designed to have limited brain penetrance, elicited potent in vitro CB<sub>1sub>R antagonist activities and iNOS inhibitory activities. Some key compounds displayed high CB<sub>1sub>R binding affinities. Compound 7 demonstrated potent in vivo pharmacological activities such as reduction of food intake mediated by the antagonism of the CB<sub>1sub>Rs and antifibrotic effect in the animal models of fibrosis mediated by iNOS inhibition and CB<sub>1sub>R antagonism.